The UK’s Office of Fair Trading announced the referral of the completed buyout of eye correction company Ultralase by competitor Optimax to the Competition Commission in what reports say suggests the OFT may have found cause of concern regarding the deal. The deal occurred in November of last year without informing the OFT; it was not until the companies’ merger was undeway that the regulator started probing the buyout. Reports say by the initiation of the review, several Ultralase clinics were already replaced by Optimax clinics. In its review, the OFT found six geographical areas whose competition was threatened by the deal. Reports say the Commission will reach a decision on the deal by January 12 of next year.
Full Content: OptometryToday
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI